top of page
Abstract Line Pattern

Prostate Cancer (mCRPC - Met Castration-Resistant)

Prostate Cancer (mCRPC - Met Castration-Resistant)

(MEVPRO-2) A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (Mevrometostat) with Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Principal Investigator (PI)

Clinical Trials.gov ID

Key Eligibility

Protocol #

SPONSOR

Pfizer
bottom of page